{
    "2019-04-06": [
        [
            {
                "time": "2019-10-15",
                "original_text": "Should Biogen Investors Be Extra Nervous Right Now?",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Investors",
                        "Nervous"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-11-05",
                "original_text": "Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Ibrance",
                        "FDA",
                        "Approval",
                        "Breast Cancer",
                        "Men"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}